At the 64th annual meeting of the American Academy of Neurology (AAN) Novartis will present the key results from a phase II dose finding study of its investigational compound BAF312 (siponimod), a selective modulator of the S1P receptor subtypes 1 and 5 (S1P1, 5-R modulator), in MS.
This double-blind placebo-controlled study applied an innovative adaptive trial design to optimally describe the dose response relationship.
A statistically significant dose response relationship could be established....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397